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Abstract
Tissue factor (TF) is best known as a cellular initiator of coagulation, but
it is also a multifunctional protein that has been implicated in multiple
pathophysiologic conditions, including asthma. In the lung, airway
epithelial cells express TF, but it is unknown how TF expression is
regulated by asthma-associated mediators. We investigated the role of
IL-13, a type 2 cytokine, alone and in combination with compressive
stress, which mimics asthmatic bronchoconstriction, on TF expression
and release of TF-positive extracellular vesicles from primary normal
human bronchial epithelial cells. Well-differentiated normal human
bronchial epithelial cells were treatedwith IL-13 and compressive stress,
alone and in combination. TF mRNA, protein and activity were
measured in the cells and conditioned media. TF was also measured in
the bronchoalveolar lavage (BAL) fluid of allergen-challengedmice and
patients with asthma. IL-13 and compressive stress increased TF
expression, but only compressive stress induced TF-positive
extracellular vesicle release. Pretreatment with IL-13 augmented
compressive stress–induced TF expression and release. TF protein
and activity in BAL fluid were increased in allergen-sensitized
and -challenged mice. TF was elevated in the BAL fluid of patients with
mild asthma after an allergen challenge. Our in vitro and in vivo data
indicate close cooperation between mechanical and inflammatory
stimuli on TF expression and release of TF-positive extracellular vesicles
in the lungs, which may contribute to pathophysiology of asthma.
Keywords: asthma; bronchoconstriction; mechanotransduction;
coagulation; airway epithelium
Clinical Relevance
Two critical components of asthma–IL-13 and
bronchoconstriction–cooperatively work to induce tissue
factor (TF) expression and release of TF-positive extracellular
vesicles from well-differentiated human bronchial epithelial
cells. Furthermore, in both mice and humans, allergen
challenge increases the release of TF into bronchoalveolar
lavage fluid.
Asthma is characterized by chronic
airway inflammation and airway
hyperresponsiveness (1, 2). Although the
immune system is certainly implicated in
asthma, a growing body of evidence
suggests that airway epithelial cells also
initiate and perpetuate disease (3, 4).
During asthma exacerbations, airway
smooth muscle contracts excessively and
the airway becomes narrowed, resulting
in buckling of the airway epithelium (5, 6).
Epithelial cells in such buckled airways
are subjected to a compressive mechanical
stress of approximately 30 cm H2O (7).
Using an in vitro system mimicking the
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buckled epithelium of constricted
airways, we previously showed that
compressive mechanical stress initiates
mechanotransduction signals in airway
epithelial cells (8, 9) and contributes to
airway remodeling in asthma (10, 11).
Importantly, the role of bronchoconstriction
in airway remodeling was validated in
humans (12). The evidence from these
studies suggests that bronchoconstriction
itself can play a major role in asthma.
A well known feature of asthma is a
procoagulant environment that is induced
by the leakage of plasma proteins into the
airway lumen (13). Although coagulation is
classically thought to happen in blood
vessels, coagulation also occurs on the
luminal surface of the airway epithelium
(14). Compared with control subjects,
coagulation activity and the concentrations
of coagulation-associated mediators,
including thrombin, thrombin–antithrombin
complex, and tissue factor (TF) are elevated
in sputum and bronchoalveolar lavage
(BAL) fluid from patients with asthma
(15–17). TF is a 47-kD transmembrane
protein that functions as the primary
cellular initiator of blood coagulation by
binding Factor VII/Factor VIIa (FVII/FVIIa)
(18, 19). It is expressed in a variety of cell
types, including airway epithelial cells (20).
Previously, we showed that TF expression is
increased in the airway epithelium of
patients with asthma and that bronchial
epithelial cells are a source of TF (21). In a
mouse model of asthma, mice with a severe
deficiency of FVII have attenuation of
airway hyperresponsiveness and mucus
production induced by allergen challenge
(22). Together, these studies suggest that
TF-dependent activation of coagulation
may contribute to asthmatic disease
presentation. Therefore, we need a better
understanding of how TF expression is
regulated in asthma.
Various inflammatory mediators and
cytokines regulate the level of TF expression
in nonepithelial cells (23), but their effect
on TF production in bronchial epithelial
cells is unknown. Here, we investigated
the effects of IL-13, a type 2 cytokine, on
TF expression and release of TF-positive
extracellular vesicles from airway epithelial
cells. IL-13 is elevated in the lungs of
patients with allergic inflammation, IL-13
expression is associated with the severity of
asthma (24, 25), and IL-13 regulates
asthma-associated genes in airway epithelial
cells (26). Though IL-13 has the capacity to
induce airway hyperresponsiveness (27, 28),
its cooperative effects with bronchospasm
on airway epithelial cells are not known.
We tested the hypothesis that IL-13
enhances compressive stress–induced TF
expression and release of TF-positive
extracellular vesicles. We also determined
the epithelial cell type expressing TF in
mouse lung, and determined whether
allergic inflammatory conditions alter the
level of TF in BAL fluid from mice. Finally,
we evaluated TF levels in BAL fluid from
patients with mild asthma after an allergen
challenge.
Materials and Methods
A detailed description of the methods is
provided in the online supplement.
Air–Liquid Interface Culture of
Primary Normal Human Bronchial
Epithelial Cells
Normal human bronchial epithelial (NHBE)
cells were obtained at passage 1 from the
Marsico Lung Institute/Cystic Fibrosis
Center at the University of North Carolina,
Chapel Hill (Chapel Hill, NC). The cells used
were obtained from five donors. Passage
2 cells were cultured and maintained in
air–liquid interface (ALI) culture for 14–17
days, as previously described (11).
In Vitro Exposure of NHBE Cells to
IL-13 or Compressive Stress
To examine the effect of IL-13 on TF
expression, NHBE cells were incubated
with recombinant IL-13 (Cell Signaling
Technology, Danvers, MA) either acutely or
chronically, at the concentration described.
For the acute exposure, cells were incubated
with IL-13 for 24 hours. For the chronic
exposure, cells were incubated with media
containing IL-13 from ALI Days 0–14.
During chronic treatment, fresh medium
with or without IL-13 was fed every other
day.
To examine the effect of IL-13 on
compressive stress–induced TF expression,
NHBE cells were incubated with IL-13
for 21 hours before the application of
compressive stress. Cells were then
exposed to 30 cm H2O pressure for 3
hours, as previously described (11). Cells
and basolateral conditioned media (CM)
were collected immediately or at the
indicated time relative to the start of
pressure. Control cells were handled
identically to experimental samples, but
were not exposed to pressure.
Measurement of Coagulation Activity
Coagulation activity of CM and of BAL fluid
was measured using a single-stage clotting
assay with normal plasma from humans
or mice, as described previously (29).
Lipidated recombinant human TF
(Innovin; Dade Behring, Marburg,
Germany) was used to generate a standard
curve. To determine the contribution of
TF to the procoagulant activity, we used
TF-blocking antibodies (clones HTF-1 or
1H1 at 10 mg/ml) to block human or mouse
TF, respectively, as previously described (30).
Allergen-Sensitized and -Challenged
Mice
All experiments were approved by the
Harvard Medical Area Standing Committee
on Animals (Harvard T. H. School of Public
Health, Boston, MA). Male mice (C57BL/6)
were purchased from Jackson laboratory
(Bar Harbor, ME). Sensitization and
challenge to ovalbumin (OVA) were
performed as previously described (31). BAL
fluid was collected 24 hours after the last OVA
inhalation, as previously described (31).
Collection of BAL Fluid from
Allergen-Challenged Patients
The protocol was reviewed by, and was
in accordance with the ethical standards
of the Partners Human Research Committee
at Brigham and Women’s Hospital (Boston,
MA). Written informed consent was
obtained by a physician from each patient.
BAL fluid was collected, as described
previously (32, 33), from patients who
had previously been diagnosed with mild
asthma. In each patient, BAL fluid was
collected immediately before a cat or
house dust mite allergen challenge, and at
48 hours after the challenge. Demographic
information and degree of eosinophil
induction after allergen challenge are
shown in Table E1 in the online
supplement. Two donors were excluded
post hoc due to a less than 1% increase in
eosinophils after the allergen challenge.
Statistical Analysis
Statistical analysis was performed in Matlab
(R2013; Mathworks, Natick, MA). A two-
tailed Student’s t test was used for datasets
with two groups. A one-way ANOVA
followed by a post hoc multiple comparison
test with the Tukey-Kramer correction was
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used to compare within datasets of three
or more groups. Statistical significance is
reported at a P value less than 0.05.
Results
IL-13 Induces TF mRNA and Protein
Expression in NHBE Cells
We examined the effect of IL-13 on TF
mRNA expression and cellular TF protein
in NHBE cells. Cells were exposed to IL-13
acutely (24 hours) or chronically (14 days).
Compared with vehicle control (0 ng/ml),
acute exposure to IL-13 at 10 and 50 ng/ml
significantly increased TF mRNA expression
by 2.1-fold and 3.1-fold, respectively
(Figure 1A). Acute exposure to IL-13
(10 ng/ml) also increased TF protein
expression (Figure 1B). Compared with
the vehicle control, chronic exposure to
IL-13 at 10 ng/ml for 14 days significantly
increased TF mRNA expression by 1.9-fold
(Figure 1C). Correspondingly,
chronic exposure to IL-13 increased
TF protein (Figure 1D). The increase
in TF by chronic IL-13 treatment was
accompanied by an increase in the number
of goblet cells (data not shown), as reported
previously (34).
Compressive Stress Increases TF
mRNA Expression in NHBE Cells and
TF Activity in the Basolateral Media
We previously showed that compressive stress
at 30 cmH2O increases TF mRNA expression
in NHBE cells (21). Here, we examined if TF
mRNA expression is dependent on the
magnitude of pressure. Compressive stress
induced TF mRNA expression in a pressure-
dependent manner (Figure 2A). Compressive
stress with 20 or 30 cm H2O pressure
significantly increased TF mRNA expression
by 2-fold or 2.3-fold, respectively, compared
with no pressure.
We previously showed that TF-positive
extracellular vesicles are released into the
basolateral CM from compressed NHBE
cells in ALI culture (21). We measured the
level of TF activity in the CM using a
clotting assay (30). Compressive stress
increased TF activity in the CM
(Figure 2B).
We next examined the localization
of TF within extracellular vesicles using
transmission electron microscopy after
immunogold labeling of the pellet obtained
via ultracentrifugation. TF is a
transmembrane protein, and, as expected,
was present in the membra1ne of
extracellular vesicles (Figure 2C).
Pretreatment with IL-13 Augments
Compressive Stress–Induced TF
mRNA Expression and Release of
TF-Positive Extracellular Vesicles
As shown previously here, both IL-13 and
compressive stress individually increase TF
mRNA and protein expression. We next
examined if IL-13 and compressive stress
cooperatively increase TF expression. We
pretreated cells with IL-13 (10ng/ml) for
21 hours followed by compressive stress for
3 hours, and then measured TF mRNA
expression. Compared with vehicle
control, IL-13 and compression alone each
significantly induced TF mRNA expression
by 1.7-fold and by 4.1-fold, respectively.
The combination of IL-13 and compression
increased TF mRNA expression by 5.5-
fold, which was significantly higher than
either stimulus alone (Figure 3A).
We then examined the effect of IL-13
on compressive stress–induced release of
TF, measured 24 hours after the initiation
of pressure. As shown in Figure 3B, TF
was undetectable in the CM from cells
incubated with either vehicle or IL-13
alone, but was present in the CM from cells
exposed to compressive stress. Compared
with compressive stress alone, pretreatment
of cells with IL-13 augmented the release
of TF into the basolateral CM (Figure 3B).
The level of TF released by compressive
stress in the absence or presence of IL-13
was quantified by densitometry analysis
(Figure 3B) on triplicate wells in three
independent experiments using primary
cells from three normal donors.
Pretreatment with IL-13 augmented
compressive stress–induced release of TF
by 2.7-fold over compressive stress alone.
TF released from compressive
stress–treated cells was exclusively detected
in the pellet after ultracentrifugation of
CM whether treated with vehicle or IL-13,
(Figure 3C). Actin was used as a marker
for the extracellular vesicle–positive
fraction (21, 35).
TF Is Elevated in the BAL Fluid of
OVA-Challenged Mice
We previously reported that TF expression
is significantly higher in the airway
epithelium and BAL fluid from subjects with
asthma versus normal subjects (21). Here,
we examined if the increase in TF
expression in patients with asthma can
be recapitulated in an allergic mouse model
of asthma. First, we examined differential
TF expression in major airway and lung
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Figure 1. IL-13 induces tissue factor (TF) expression in normal human bronchial epithelial (NHBE)
cells. TF expression was determined in NHBE cells after acute (A and B; at 10 or 50 ng/ml for
24 hours) or chronic (C and D; at 10 ng/ml for 14 days) exposure to IL-13. (A and C) TF mRNA
expression (A, acute, four donors; C, chronic, one donor) was normalized to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression (mean6 SD). (B and D) Representative blots of
cellular TF detected by Western blot analysis (B, acute; D, chronic). E-cadherin was used as a loading
control in B, whereas GAPDH was used as a loading control in D. Grayscale shading corresponds to
amount of cytokine used (A and C). *P , 0.05 versus 0 ng/ml.
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epithelial cells to determine which is the
major cell type expressing TF. Among lung
epithelial cells that we examined, basal
cells showed the highest level of TF mRNA
expression, over club and type 2 epithelial
cells (Figure 4A). To confirm TF protein
expression in basal cells, we analyzed TF
protein by immunofluorescence staining
in mouse trachea. TF was abundantly
expressed in the layer of cells that costained
with an antibody against p63, a basal cell
marker (Figure 4B). TF staining was also
detected on the luminal surface of the
epithelium.
Using Western blot analysis, we
detected TF in BAL fluid collected from
mice (21). Compared with BAL fluid
from PBS-challenged mice, BAL fluid from
OVA-challenged mice had significantly
elevated levels of TF, confirmed by
densitometry analysis (Figure 5A). We
also examined TF activity of the BAL
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Figure 3. Pretreatment of IL-13 augments TF production in NHBE cells. TF mRNA expression
(A, mean6 SEM, two donors) and released TF were determined (B, mean6 SEM, three donors) in
the presence or absence of IL-13 (at 10 ng/ml for 24 hours). In the representative Western blot
detections of TF in the whole CM (B and C) and in the extracellular vesicle fraction (C), Coomassie
staining of SDS-PAGE (B) or actin (C) was used as a loading control. *P, 0.05 versus control, #P,
0.05 versus compressive stress alone. Comp., compressive stress; Ctrl., control; Pellet, extracellular
vesicle fraction; Sup., supernatant; Veh., vehicle. Grayscale shading corresponds to amount of
cytokine used, whereas diagonal stripes indicate the application of compressive stress (A and B).
ORIGINAL RESEARCH
Mitchel, Antoniak, Lee, et al.: IL-13 Augments Tissue Factor Expression 527
fluid and found that OVA-challenged mice
had significantly greater TF activity
compared with controls (Figure 5B). Last,
we isolated extracellular vesicles using
ultracentrifugation to determine if TF
released into BAL fluid is contained in
extracellular vesicles. TF was detected in the
pellet, not exclusively, but predominantly,
in both PBS-challenged and OVA-
challenged mice (Figure 5C).
TF Is Elevated after Allergen
Challenge in Patients with Asthma
To determine if TF is released into the
airways of patients with asthma during
asthma exacerbations, we detected TF in the
BAL fluid of patients before and after
exposure to an allergen challenge. The
BAL fluid was collected from patients
immediately before instillation of an allergen
into the lungs, and collected again from the
same location 48 hours later. Compared
with the preallergen samples, TF protein levels
were significantly higher in the postallergen
samples in all patients (Figure 6).
Discussion
The mechanotransduction paradigm (36) of
asthma pathogenesis hypothesizes that,
even in the absence of inflammatory cells,
compressive mechanical stimulation of
airway epithelial cells initiates signaling
cascades causing airway remodeling (9).
This hypothesis has been tested in vitro
(10, 11) and in humans (12). However,
during asthmatic disease progression,
we cannot separate the effects of
bronchoconstriction from inflammation,
as both occur. In fact, our data suggest
that the production of TF is augmented
in the inflamed airways as a result of
the cooperative actions of pre-existing
inflammatory mediators and
bronchoconstriction. To test our
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(B) Representative immunofluorescence staining
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a marker for basal cells. Arrowheads indicate
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hypothesis, we used an in vitro model
of bronchoconstriction and a mouse model
of allergic inflammation. Finally, to validate
our findings, we used BAL fluid collected
from patients with mild asthma after an
allergen challenge.
From the multiple inflammatory
mediators implicated in dysregulation of
the airway epithelium in asthma, we chose
to examine the type 2 cytokine, IL-13
(37, 38). In vitro and in vivo experiments
have shown that IL-13 induces airway
hyperresponsiveness (27, 28) and reduces
b-adrenoreceptor–induced smooth muscle
relaxation (39). The concentration of IL-13
is elevated in BAL fluid from many patients
with asthma (40), and, therefore, IL-13
and compressive mechanical stress may
act in concert in the asthmatic airway.
Exposure of airway epithelial cells to IL-13
is well recognized to modify the expression
of a variety of genes and proteins that play
roles in asthma (26), although the effect of
IL-13 on TF expression was unknown. We
found that both acute and chronic exposure
to IL-13 induced TF mRNA expression and
cellular TF protein.
In our previous study, we reported that
compressive stress at a magnitude of 30 cm
H2O pressure, which is the estimated
compression in a maximally constricted
airway (7), induces both mRNA expression
and release of TF-positive extracellular
vesicles from NHBE cells. We showed that TF
mRNA expression is induced maximally at
3 hours and returns to baseline by 24 hours.
Here, we find that compressive stress induced
TF mRNA expression in a magnitude-of-
pressure–dependent manner, rather than as a
threshold effect. Therefore, we can speculate
that the degree of TF production in the
airway may depend on the severity of
bronchoconstriction in patients with asthma,
and suggest that bronchodilators not only
relax constricted airways, but may also reduce
the abnormal presence of TF.
In a recent study, Sebag and colleagues
(41) found that mechanical stretch reduces
LPS-induced TF mRNA expression,
although mechanical stretch alone did
not change TF mRNA expression. The
discrepancy between our studies in
TF mRNA expression may be due to
differences in the type or duration of
mechanical stimulation applied, or the use of
different cell types. In particular, Sebag and
colleagues used MLE12, alveolar type
II–derived cells, from murine lungs, whereas
we used primary NHBE cells from human
airways. Despite the apparent contradiction
in mRNA expression after mechanical
stimuli, both studies support the conclusion
that mechanical stimuli can alter TF-derived
coagulation activity in the lung.
Coagulation activity in the airway
lumen is critical for fibrin accumulation
and asthma pathogenesis (42–44), and
coagulant and fibrinolytic mediators can
directly mediate inflammatory responses
in the lung (45). Therefore, we
determined the coagulation activity of
CM. The coagulation activity of CM from
compressed NHBE cells was totally
abrogated by a TF-blocking antibody,
indicating that the coagulation activity
was TF dependent. These findings show
that bronchial epithelial cells release active
TF in response to compressive stress.
We confirmed that TF is localized to the
membrane of released extracellular vesicles.
Both IL-13– and bronchoconstriction-
induced mechanical stress are important in
asthma, but their cooperative role has never
been studied. Here, we tested if priming
airway epithelial cells with IL-13 can
exaggerate TF production. Pretreatment of
NHBE cells with IL-13 augmented the
compressive stress–induced responses,
mRNA expression, and release of TF-
positive extracellular vesicles. Regardless
of pretreatment, TF was released in
extracellular vesicles. Although the function
of TF released from bronchial epithelial
cells remains unknown, TF contained in
extracellular vesicles has the capacity to
activate neighboring cells and the local
microenvironment (18, 46). Together with
the coagulation activity of CM from
compressed cells, these data suggest that
constriction of airway epithelial cells
directly modulates their biochemical
properties, and also indirectly modulates
the airway microenvironment.
To validate our in vitro findings in a
biologically relevant asthma model, we used
a mouse model of allergic inflammation
using OVA. Our data are the first to
show enhanced TF expression under
allergic inflammatory conditions in mice,
indicating that this model will be useful for
studying the function of TF in asthma. The
distribution of TF in mouse lung epithelial
cells was unknown, although, in humans, it
is considered a basal cell marker (47, 48).
We show that, as in humans, TF is
abundantly expressed in basal epithelial
cells in the mouse airway. Compared with
mice exposed to PBS, TF and coagulation
activity were significantly elevated in the
BAL fluid collected from sensitized and
challenged mice. These data recapitulate
our previous observation that the airway
epithelium of patients with asthma
expresses a higher level of TF than that of
control subjects (21).
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To highlight our findings in vitro and in
mouse studies, we used materials collected
from patients with asthma who had been
challenged with allergen. In all patients
tested, the level of TF was elevated in the
BAL fluid at 48 hours after a single challenge
compared with BAL fluid collected from the
same subjects before allergen challenge.
Schouten and colleagues (49) previously
showed that exposure to allergens increases
the availability of TF in BAL fluid from
patients with asthma at 4 hours after
exposure. Here, we see that the effect
of allergen challenge on available TF can
be persistent over 2 days, potentially
contributing to generation of an abnormally
procoagulant microenvironment and
chronic inflammation (13, 50) and aspects
of airway remodeling (18, 51).
Although the role of TF has not yet been
unequivocally established, our data suggest
that TF is implicated in asthma pathogenesis.
In addition to its well established role as a
cellular initiator of coagulation, TF also plays
a pathological role in a variety of diseases,
including thrombosis, cancer, diabetes, and
acute lung respiratory syndrome (52). As a
pathologic mediator, TF contributes to
coagulation, inflammation, cell migration,
and angiogenesis, all of which occur during
tissue remodeling (18, 53). Although
approaches using TF-deficient mice will
clearly elucidate the role of TF in asthma, we
speculate here that TF plays a role in the
remodeling process that occurs in asthmatic
airways.
This is the first study to examine
the combined action of biochemical
and mechanical stimuli that could act
cooperatively in the asthmatic airway
epithelium. The responsiveness of epithelial
cells to compressive stress can be
exaggerated by the presence of a pre-existing
asthma mediator. We tested our hypothesis
that IL-13 enhances compressive
stress–induced TF expression and release of
TF-positive extracellular vesicles. The
in vitro data show that compressive stress
and IL-13 both act at the transcriptional
level to increase mRNA expression of TF in
NHBE cells, whereas only compressive
stress acts to cause the release of
membrane-bound TF into extracellular
vesicles. The increased level of TF in
BAL fluid from mice and humans
challenged with allergen also supports the
possible role of TF in asthma. Taken
together, our results show that the
availability of active TF in the lung was
substantially increased by conditions
associated with asthma. n
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